Nelson L Michael
Michael, Nelson L.
Michael, Nelson
VIAF ID: 39551076 (Personal)
Permalink: http://viaf.org/viaf/39551076
Preferred Forms
- 200 _ | ‡a Michael ‡b Nelson L.
- 100 1 0 ‡a Michael, Nelson
- 100 1 _ ‡a Michael, Nelson L.
- 100 1 _ ‡a Michael, Nelson L.
-
- 100 0 _ ‡a Nelson L Michael
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
HIV protocols | |
Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda | |
Improved outlook on HIV-1 prevention and vaccine development | |
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | |
Individual and Sexual Network Predictors of HIV Incidence Among Men Who Have Sex With Men in Nigeria | |
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans | |
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses | |
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees | |
Influence of HLA-C expression level on HIV control | |
Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation | |
Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology | |
Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation | |
Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans | |
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations | |
An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens | |
Joint United Nations Programme on HIV/AIDS | |
Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. | |
Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers | |
Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings | |
Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence ugandan blood bank population | |
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection | |
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection | |
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial | |
Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study | |
Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual | |
Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. | |
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations | |
Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees | |
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials | |
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification | |
A novel acute HIV infection staging system based on 4th generation immunoassay | |
A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection | |
A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism. | |
The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 | |
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). | |
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. | |
A pilot online survey assessing risk factors for HIV acquisition in the Navy and Marine Corps, 2005-2010. | |
Population-based Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis prevalence using discarded, deidentified urine specimens previously collected for drug testing | |
The protective effect of circumcision on HIV incidence in rural low-risk men circumcised predominantly by traditional circumcisers in Kenya: two-year follow-up of the Kericho HIV Cohort Study | |
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection | |
Rare serotype adenoviral vectors for HIV vaccine development | |
RecDraw: a software package for the representation of HIV-1 recombinant structures. | |
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination | |
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity | |
Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials | |
Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya | |
Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda | |
Review of the U.S. military's human immunodeficiency virus program: a legacy of progress and a future of promise | |
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | |
The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization | |
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene | |
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial | |
Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost | |
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand | |
A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants | |
Sensitivity of the Multispot HIV-1/HIV-2 rapid test using samples from human immunodeficiency virus type 1-positive individuals with various levels of exposure to highly active antiretroviral therapy. | |
Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. | |
Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations | |
Sexually transmitted infections and sexual behaviour of deploying shipboard US military personnel: a cross-sectional analysis | |
Short communication: HIV type 1 genetic diversity among tea plantation workers in Kericho, Kenya | |
Short communication: Investigation of incident HIV infections among U.S. army soldiers deployed to Afghanistan and Iraq, 2001-2007. | |
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. | |
Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG. | |
Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection. | |
Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes | |
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee | |
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. | |
Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform | |
Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity | |
TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1 | |
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope | |
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques | |
Transcription regulation of human chemokine receptor CCR3: evidence for a rare TATA-less promoter structure conserved between drosophila and humans. | |
Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. | |
Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom | |
Transfusion-transmitted human T-lymphotropic virus Type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010. | |
Use of rapid and conventional testing technologies for human immunodeficiency virus type 1 serologic screening in a rural Kenyan reference laboratory | |
Use of stored serum from Uganda for development and evaluation of a human immunodeficiency virus type 1 testing algorithm involving multiple rapid immunoassays | |
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. | |
A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials | |
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses | |
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | |
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. | |
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | |
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | |
Vaccine protection against Zika virus from Brazil | |
Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. | |
Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania | |
Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand | |
Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection |